ADMA Biologics Faces Class Action Over Alleged Channel Stuffing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Lawsuit Background: Berger Montague PC has filed a class action lawsuit against ADMA Biologics, alleging that the company engaged in channel stuffing from August 9, 2024, to March 25, 2026, in an attempt to drive revenue growth amid declining demand for ASCENIV, which undermines investor confidence.
- Financial Manipulation Allegations: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, resulting in a reported 20% revenue growth in 2025 that was not genuine; without this scheme, the company would have faced a 3% revenue decline.
- Stock Price Reaction: Following the lawsuit announcement, ADMA's stock price plummeted from $13.59 on March 23, 2026, to $11.33, a 16% drop, and fell another 15% to $9.63 the next day, reflecting market concerns over the company's financial transparency.
- Investor Action: Investors must apply by August 10, 2026, to be appointed as lead plaintiffs in the class action, highlighting concerns over corporate governance and financial reporting that could impact future investment decisions and the company's reputation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Faces Class Action Over Alleged Channel Stuffing
- Lawsuit Background: Berger Montague PC has filed a class action lawsuit against ADMA Biologics, alleging that the company engaged in channel stuffing from August 9, 2024, to March 25, 2026, in an attempt to drive revenue growth amid declining demand for ASCENIV, which undermines investor confidence.
- Financial Manipulation Allegations: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, resulting in a reported 20% revenue growth in 2025 that was not genuine; without this scheme, the company would have faced a 3% revenue decline.
- Stock Price Reaction: Following the lawsuit announcement, ADMA's stock price plummeted from $13.59 on March 23, 2026, to $11.33, a 16% drop, and fell another 15% to $9.63 the next day, reflecting market concerns over the company's financial transparency.
- Investor Action: Investors must apply by August 10, 2026, to be appointed as lead plaintiffs in the class action, highlighting concerns over corporate governance and financial reporting that could impact future investment decisions and the company's reputation.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against ADMA Biologics in the U.S. District Court for New Jersey on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026, indicating significant legal risks for the company.
- Detailed Allegations: The lawsuit alleges that ADMA failed to disclose related party transactions, engaged in channel stuffing to inflate revenue, and lacked adequate internal controls, potentially misleading investors about the company's financial health and impacting their investment decisions.
- Stock Price Volatility: Following the release of a short report by Culper Research, ADMA's stock price fell by $2.26, or 16.63%, to close at $11.33 per share on March 24, 2026, reflecting market concerns regarding the company's financial stability.
- Investor Action Encouraged: The law firm urges investors who suffered losses during the class period to reach out for legal support, demonstrating the firm's commitment to protecting investor rights and providing assistance in navigating the legal process.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) for securities fraud, alleging significant misstatements and omissions in financial reporting during the period from August 9, 2024, to March 25, 2026, which undermines investor confidence.
- Key Allegations: The lawsuit claims that ADMA engaged in undisclosed related party transactions and used channel stuffing to inflate revenues, lacking adequate internal controls, which rendered the company's positive business outlook misleading and potentially harmful to investors.
- Stock Price Reaction: Following a report by Culper Research on March 24, 2026, alleging channel stuffing, ADMA's stock price plummeted by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, indicating severe market concerns regarding the company's financial health.
- Investor Action: Affected investors must file for lead plaintiff status by August 10, 2026, to represent other investors in the lawsuit, with KTMC offering free case evaluations, emphasizing that there are no costs involved for investors during this process.
See More
ADMA Biologics Faces Class Action Over Alleged Internal Control Failures
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for alleged securities fraud during the period from August 9, 2024, to March 25, 2026, claiming false statements regarding the effectiveness of internal controls led to investor losses.
- Revenue Growth Dispute: A March 2026 research report alleged that ADMA's reported 20% revenue growth was fictitious, estimating actual growth at negative 3%, which directly impacts investors' perceptions of the company's financial health.
- Internal Control Failures: The lawsuit asserts that ADMA certified its disclosure controls as effective across seven consecutive SEC filings while concealing related party transactions with
See More
ADMA Biologics Investors Class Action Lawsuit Announced
- Class Action Notice: The Portnoy Law Firm informs ADMA Biologics investors of a class action lawsuit for those who purchased securities between August 9, 2024, and March 25, 2026, with a deadline of August 10, 2026, to file a lead plaintiff motion to protect their legal rights.
- Legal Allegations: The complaint alleges that ADMA and certain executives failed to disclose material information in the Offering Documents, violating federal securities laws, including undisclosed related party transactions, channel stuffing to create an appearance of revenue, and inadequate internal controls, leading to investor losses.
- Investor Damages: When the true details emerged in the market, investors suffered damages due to ADMA's false and misleading statements, indicating that the company's representations about its business, operations, and prospects were materially false and misleading at all relevant times.
- Law Firm Background: The founding partner of the Portnoy Law Firm has recovered over $5.5 billion for aggrieved investors, showcasing their extensive experience and success in handling such cases, allowing investors to seek legal support to recover their losses.
See More
ADMA Biologics Class Action Lawsuit Notice
- Class Action Initiation: ADMA Biologics faces a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with the class period from August 9, 2024, to March 25, 2026, requiring investors to apply as lead plaintiffs by August 10, 2026, which could impact the company's reputation and stock price.
- False Statement Allegations: The lawsuit alleges that ADMA Biologics made false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing practices, potentially leading to decreased investor confidence and stock price volatility.
- Stock Price Volatility: According to the complaint, ADMA Biologics' stock price fell over 16% following the release of a report by Culper Research on March 24, 2026, and dropped again by over 13% after the company's response, indicating market concerns regarding the company's financial transparency.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, showcasing its strength in securities class actions, which may influence ADMA's legal strategy.
See More
ADMA Biologics Faces Class Action Over Alleged Channel Stuffing
- Lawsuit Background: Berger Montague PC has filed a class action lawsuit against ADMA Biologics, alleging that the company engaged in channel stuffing from August 9, 2024, to March 25, 2026, in an attempt to drive revenue growth amid declining demand for ASCENIV, which undermines investor confidence.
- Financial Manipulation Allegations: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, resulting in a reported 20% revenue growth in 2025 that was not genuine; without this scheme, the company would have faced a 3% revenue decline.
- Stock Price Reaction: Following the lawsuit announcement, ADMA's stock price plummeted from $13.59 on March 23, 2026, to $11.33, a 16% drop, and fell another 15% to $9.63 the next day, reflecting market concerns over the company's financial transparency.
- Investor Action: Investors must apply by August 10, 2026, to be appointed as lead plaintiffs in the class action, highlighting concerns over corporate governance and financial reporting that could impact future investment decisions and the company's reputation.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against ADMA Biologics in the U.S. District Court for New Jersey on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026, indicating significant legal risks for the company.
- Detailed Allegations: The lawsuit alleges that ADMA failed to disclose related party transactions, engaged in channel stuffing to inflate revenue, and lacked adequate internal controls, potentially misleading investors about the company's financial health and impacting their investment decisions.
- Stock Price Volatility: Following the release of a short report by Culper Research, ADMA's stock price fell by $2.26, or 16.63%, to close at $11.33 per share on March 24, 2026, reflecting market concerns regarding the company's financial stability.
- Investor Action Encouraged: The law firm urges investors who suffered losses during the class period to reach out for legal support, demonstrating the firm's commitment to protecting investor rights and providing assistance in navigating the legal process.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) for securities fraud, alleging significant misstatements and omissions in financial reporting during the period from August 9, 2024, to March 25, 2026, which undermines investor confidence.
- Key Allegations: The lawsuit claims that ADMA engaged in undisclosed related party transactions and used channel stuffing to inflate revenues, lacking adequate internal controls, which rendered the company's positive business outlook misleading and potentially harmful to investors.
- Stock Price Reaction: Following a report by Culper Research on March 24, 2026, alleging channel stuffing, ADMA's stock price plummeted by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, indicating severe market concerns regarding the company's financial health.
- Investor Action: Affected investors must file for lead plaintiff status by August 10, 2026, to represent other investors in the lawsuit, with KTMC offering free case evaluations, emphasizing that there are no costs involved for investors during this process.
See More
ADMA Biologics Faces Class Action Over Alleged Internal Control Failures
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for alleged securities fraud during the period from August 9, 2024, to March 25, 2026, claiming false statements regarding the effectiveness of internal controls led to investor losses.
- Revenue Growth Dispute: A March 2026 research report alleged that ADMA's reported 20% revenue growth was fictitious, estimating actual growth at negative 3%, which directly impacts investors' perceptions of the company's financial health.
- Internal Control Failures: The lawsuit asserts that ADMA certified its disclosure controls as effective across seven consecutive SEC filings while concealing related party transactions with
See More
ADMA Biologics Investors Class Action Lawsuit Announced
- Class Action Notice: The Portnoy Law Firm informs ADMA Biologics investors of a class action lawsuit for those who purchased securities between August 9, 2024, and March 25, 2026, with a deadline of August 10, 2026, to file a lead plaintiff motion to protect their legal rights.
- Legal Allegations: The complaint alleges that ADMA and certain executives failed to disclose material information in the Offering Documents, violating federal securities laws, including undisclosed related party transactions, channel stuffing to create an appearance of revenue, and inadequate internal controls, leading to investor losses.
- Investor Damages: When the true details emerged in the market, investors suffered damages due to ADMA's false and misleading statements, indicating that the company's representations about its business, operations, and prospects were materially false and misleading at all relevant times.
- Law Firm Background: The founding partner of the Portnoy Law Firm has recovered over $5.5 billion for aggrieved investors, showcasing their extensive experience and success in handling such cases, allowing investors to seek legal support to recover their losses.
See More
ADMA Biologics Class Action Lawsuit Notice
- Class Action Initiation: ADMA Biologics faces a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with the class period from August 9, 2024, to March 25, 2026, requiring investors to apply as lead plaintiffs by August 10, 2026, which could impact the company's reputation and stock price.
- False Statement Allegations: The lawsuit alleges that ADMA Biologics made false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing practices, potentially leading to decreased investor confidence and stock price volatility.
- Stock Price Volatility: According to the complaint, ADMA Biologics' stock price fell over 16% following the release of a report by Culper Research on March 24, 2026, and dropped again by over 13% after the company's response, indicating market concerns regarding the company's financial transparency.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, showcasing its strength in securities class actions, which may influence ADMA's legal strategy.
See More
